On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth.

The results of the trial, called IMPACT, were published in the journal The Lancet.